Company: JUNS
Filing Date: 2025-11-07
Form Type: DEFA14A
Source: 0001493152-25-021317
Chunk: 1

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-07
Form: DEFA14A
Chunk 1
---
 to the Proxy Statement as amended and supplemented by this Supplement.
This Supplement should be read in conjunction with the Proxy Statement and the other proxy materials previously made available to stockholders
in connection with the Annual Meeting.

If you have already voted
your shares, you do not need to vote again unless you would like to change or revoke your prior vote on any proposal.

Corrections to the Proxy Statement

Page 44: In Proposal No. 5, the maximum
number of shares of the Company’s common stock, par value of $0.0001 (the “Common Stock”) that the Company may
issue unless the Company obtains the requisite stockholder approval to issue shares of Common Stock in excess of the Exchange Cap to Yorkville
under the SEPA and upon conversion of the Convertible Notes in accordance with applicable Nasdaq rules is amended and restated in the
following paragraph to read as follows (corrections are marked, with new text bold and underlined, and deleted text stricken through):

Under the applicable Nasdaq rules,
in no event may the Company issue to Yorkville under the SEPA or upon conversion of the Convertible Notes, collectively, more than 6,638,088 6,855,459 shares of Common Stock, which number of shares is equal to 19.99% of the shares of Common Stock outstanding immediately
prior to the execution of the SEPA (the “Exchange Cap”), unless the Company obtains the requisite stockholder approval
to issue shares of Common Stock in excess of the Exchange Cap to Yorkville under the SEPA and upon conversion of the Convertible Notes
in accordance with applicable Nasdaq rules. At the upcoming 2025 annual meeting of the Company’s stockholders to be held on December
19, 2025 (the “Annual Meeting”), among other things, the Company will seek the requisite stockholder approval in accordance
with Rule 5635(d) of the Nasdaq Listing Rules (in addition to the requisite stockholder approval under Nasdaq Listing Rule 5635(b)) to
issue and sell shares of Common Stock in excess of the 6,855,459 share Exchange Cap referred
to above to Yorkville under the SEPA and upon conversion of the Convertible Notes. Accordingly, if such requisite stockholder approval
is obtained at the Annual Meeting, the Company would be able to issue and sell to Yorkville in Advances under the SEPA as many shares
of Common Stock as will be necessary for the Company to obtain the entire $20.0